Diagnosis and management of migraine in family practice

Journal of Family Practice

Volumn 53, Issue SUPPL. 1, 2004, Pages

  Taylor, Frederick ^a   Hutchinson, Susan ^b   Graff Radford, Steven ^c   Cady, Roger ^d   Harris, Lisa ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Women's Medical Group of Irvine   (United States)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d HEADACHE CARE CENTER   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETACHRON E R; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROERGOCRISTINE METHANESULFONATE; ELETRIPTAN; ERGOT DERIVATIVE; FLUOXETINE; FLUVOXAMINE MALEATE; FROVATRIPTAN; GABAPENTIN; METOCLOPRAMIDE; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; NARATRIPTAN; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TIMOLOL MALEATE; TOPIRAMATE; VALPROATE SEMISODIUM; VERAPAMIL; ZOLMITRIPTAN; VASOCONSTRICTOR AGENT;

AGITATION; ANAMNESIS; BEHAVIOR THERAPY; CLINICAL PRACTICE; CLUSTER HEADACHE; COGNITIVE THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOSE RESPONSE; GENERAL PRACTICE; HEADACHE; HUMAN; MIGRAINE; NAUSEA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; TENSION HEADACHE; TREATMENT PLANNING; TREMOR; ADOLESCENT; ADULT; ARTICLE; FEMALE; HEADACHE AND FACIAL PAIN; MALE; METHODOLOGY; MIDDLE AGED; PATIENT CARE; PATIENT EDUCATION;

ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; FAMILY PRACTICE; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT EDUCATION; PATIENT-CENTERED CARE; VASOCONSTRICTOR AGENTS;

EID: 0347087393     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646-657.
2. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Available at: www.aan.com/public/practiceguide lines/03.pdf. Accessed 16 February 2002.
3. Mannix LK. Epidemiology and impact of primary headache disorders. Med Clin North Am 2001; 85:887-895.
4. Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin 2001; 17:298-309.
5. Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics 2001; 19:231-244.
6. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci 1999; 26(suppl 3):S12-S19.
7. Freitag FG. Acute treatment of migraine and the role of triptans. Curr Neurol Neurosci Rep 2001; 1:125-132.
8. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41:638-645.
9. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004; 24(suppl 1):1-151.
10. Dodick DW. Diagnosing headache: clinical clues and clinical rules. Adv Stud Med 2003; 3:87-92.
11. Sheftell FD, Tepper SJ. New paradigms in the recognition and acute treatment of migraine. Headache 2002; 42:58-69.
12. Inan LE, Tulunay FC, Guvener A, Tokgoz G, Inan N. Characteristics of headache in migraine without aura and episodic tension-type headache in the Turkish population according to the IHS classification. Cephalalgia 1994; 14:171-173.
13. Spierings ELH, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine versus tension-type headache. Headache 2001;41:554-558.
14. Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology 2002; 58(suppl 6):S15-S20.
15. Couch JR. Sinus headache: a neurologist's viewpoint. Semin Neurol 1988; 8:298-302.
16. Diamond ML. The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology 2002; 58(suppl 6):S3-S9.
17. Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002; 58(suppl 6):S10-S14.
18. Barbanti P, Fabbrini G, Pesare M, Vanacore N, Cerbo R. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 2002; 22:256-259.
19. Cady R, Dodick DW. Diagnosis and treatment of migraine. Mayo Clin Proc 2002; 77:255-261.
20. Lipton RB, Cady RK, Stewart WF, Wilks K, Hall C. Diagnostic lessons from the Spectrum Study. Neurology. 2002;58(suppl 6):S27-S31.
21. Tepper S, Newman L, Dowson A, et al. The prevalence and diagnosis of migraine in a primary care setting in the United States-insights from the Landmark Study. Poster presented at the Annual Scientific Meeting of the American Headache Society; June 21-23, 2002; Seattle, Wash.
22. Zakrzewska JM. Management overview. In: Zakrzewska JM, Harrison SD, eds. Assessment and Management of Orofacial Pain: Pain Research and Clinical Management. Elsevier Science, 2002:132-179.
23. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39(suppl 2):S20-S26.
24. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan: IV: patient satisfaction. Pharmacoeconomics 1997; 11(suppl 1):43-50.
25. Lipton RB, Stewart WF, Stone AM, Láinez MJA. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284:2599-2605.
26. Cady RK, Sheftell F, Lipton RB, et al. Effects of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22:1035-1048.
27. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40:792-797.
28. Rapaport A, Williams P, Sawyer J. Stratified care: cost efficient in the management of migraine. Montreal, 2000 Proceedings of the 42nd Annual Meeting of the American Headache Society, PP 222-223.
29. Wiederholt SC. Neurology for non-neurologists. In: eds. Headache. Philadelphia, Pa: WB Saunders Company; 2000:65-88.
30. Salonen R, Scott A. Triptans: do they differ? Curr Pain Headache Rep 2002; 6:133-139.
31. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 19:232-240.
32. Freitag FG, Cady R, Elkind A, et al. Comparative study of Midrin and sumatriptan suceinate in the treatment of migraine headache [abstract]. Headache 1999; 39:354.
33. Boureau F, Chazot G, Emile J, Bertin L, d'Allens H. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study. Eur Neurol 1995; 35:264-269.
34. Wenzel RG, Sarvis CA, Irause ML. Over-the counter drugs for acute migraine attacks: Literature review and recommendations. Pharmacotherapy 2003; 23:494-505.
35. Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs 1999; 58:699-723.
36. Stark S, O'Quinn S, McNeal S, et al. Naratriptan is effective for the treatment of migraine headache in sumatriptan non-responders [abstract]. Headache 1999; 39.
37. Mathew NT, Kailasam F, Meadors L, et al. Treatment of oral sumatriptan nonresponders with 5 mg zolmitriptan and 10 mg rizatriptan: A comparative open trial [abstract]. Headache 1999; 39:368.
38. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34:476-478.
39. Magnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999; 40(suppl 6):S66-S72.
40. Hays P. Paroxetine prevents migraines [letter]. J Clin Psychiatry 1997; 58:30-31.
41. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999; 39:129-199.
42. Storey JR, Calder Cs, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41(10):968-975.
43. Brandes JL, Jacobs D, Neto W, Bhattacharaya S. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, parallel study (MIGR-002). [Abstract]. Neurology 2003; 60:P03.155.
44. Diamond S, Ryan RE, Klapper JA, et al. Dotarizine in the prophylaxis of migraine headaches [abstract]. Headache. 1999;39:350.
45. Saper JR, Lake AE, Hamel RL, et al. Long-term schedules of opioid treatment for intractable headache: third year outcome of a five year study [abstract]. Headache 1999; 39:380.
46. Ziegler DK. Opioids in headache treatment. Is there a role? Neurol Clin. 1997; 15:199-207.
47. Klapper J, Mathew N, Saper J, et al. A multicenter, double-blinded, placebo-controlled trial of two dosages of Botox in the prophylactic treatment of migraine [abstract]. Headache 1999; 39:361.
48. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache. 1992;32:509-513.
49. Marcus DA, Scharff L, Mercer SR, et al. Nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback. Cephalalgia 1998; 18:266-272.
50. Warner G. Relaxation therapy in migraine and chronic tension headache. Med J Aust 1975; 1:298-301.
51. Payne TJ, Stetson B, Stevens VM, Johnson CA, Penzien DB, Van Dorsten B. The impact of cigarette smoking on headache activity in headache patients. Headache 1991; 31:329-332.